|
|
Volumn 29, Issue 10, 2011, Pages 856-858
|
|
Pertuzumab to bolster Roche/Genentech's breast cancer franchise?
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
EPIDERMAL GROWTH FACTOR RECEPTOR 2;
ERBB2 PROTEIN, HUMAN;
MONOCLONAL ANTIBODY;
PERTUZUMAB;
TRASTUZUMAB;
BREAST TUMOR;
DRUG APPROVAL;
DRUG INDUSTRY;
ECONOMICS;
FEMALE;
HUMAN;
IMMUNOLOGY;
NOTE;
PHASE 2 CLINICAL TRIAL (TOPIC);
PHASE 3 CLINICAL TRIAL (TOPIC);
PROGNOSIS;
PROTEIN MULTIMERIZATION;
SIGNAL TRANSDUCTION;
TREATMENT OUTCOME;
ANTIBODIES, MONOCLONAL, HUMANIZED;
BREAST NEOPLASMS;
CLINICAL TRIALS, PHASE II AS TOPIC;
CLINICAL TRIALS, PHASE III AS TOPIC;
DRUG APPROVAL;
DRUG INDUSTRY;
FEMALE;
HUMANS;
PROGNOSIS;
PROTEIN MULTIMERIZATION;
RECEPTOR, ERBB-2;
SIGNAL TRANSDUCTION;
TREATMENT OUTCOME;
|
|
EID: 84856391026
PISSN: None
EISSN: 15461696
Source Type: Journal
DOI: 10.1038/nbt1011-856b Document Type: Note |
|
Times cited : (2)
|
|
References (0)
|
